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Synonyms 
Ionotropic glutamate receptors (AMPA, kainate and NMDA receptors); Metabotropic glutamate 
receptors 
 
Nomenclature of Glutamate Receptor Proteins 
International Union of Basic and Clinical Pharmacology (IUPHAR) recommended and previous 
nomenclatures of glutamate receptor proteins 
1. Ionotropic glutamate receptors (Traynelis et al. 2010) 
• AMPA receptor subunits GluA1-4 (previously: GluR1-4; GluRA-D; GLUA1-4) 
• Kainate receptor subunits GluK1-5 (previously: GluR5-7, KA-1/2; EAA3-5, EAA1/2; GLUK5-7, 
GLUK1/2) 
• NMDA receptor subunits GluN1, GluN2A-D, GluN3A-B (previously: NR1, NR2A-D, NR3A/B; 
GLUN1, GLUN2A-D, GLUN3A/B) 
• δ receptor subunits GluD1-2 (previously: GluRδ1/2) 
2. Metabotropic glutamate receptors (Niswender and Conn 2010) 
• mGlu1-8 (previously: mGluR1-8) 
 
Historical Background 
The excitatory neurotransmitter role of L-glutamate gradually emerged in the 1950s–1960s. Early 
studies indicated that L-glutamate: (1) was present in high concentrations throughout the mammalian 
central nervous system (CNS), (2) produced convulsions, and (3) excited single neurons (reviewed 
in Lodge 2009). The development of increasingly specific pharmacological tools during the 1970s 
started to reveal considerable functional diversity. The family of glutamate-activated cation channels 
(ionotropic glutamate receptors [iGluRs]) was classified into three major pharmacological 
subfamilies, defined by their most selective agonists: α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionate (AMPA), kainate, and N-methyl-D-aspartate (NMDA) receptors (Lodge 2009; Traynelis et 
al. 2010). In the mid-1980s, evidence began to appear of the existence of another glutamate receptor 
(GluR) group termed metabotropic GluRs (mGluRs) that are directly coupled to second-messenger 
systems via GTP-binding proteins (Nicoletti et al. 2011). However, iGluR and mGluR proteins 
remained elusive until the late 1980s. The application of the newly emerging expression cloning 
approach led to a breakthrough and provided the original sequence information for the first iGluR 
subunits GluA1 and GluN1 (Lodge 2009). The first member of the family of mGluRs (mGlu1a) was 
also discovered by expression cloning (Nicoletti et al. 2011). Successive cloning by sequence 
homology led to the identification of additional iGluR subunits, mGluR isoforms, and their splice 
variants (Traynelis et al. 2010; Niswender and Conn 2010). Receptor localization studies in the 
1990s–2000s, together with the development of a range of transgenic animals and more selective 
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pharmacological tools, started to reveal the mechanisms of glutamatergic signaling in the CNS. The 
availability of X-ray crystal structures, molecular modeling and site-directed mutagenesis studies 
provided much improved understanding of the molecular organization of iGluRs (Kumar and Mayer 
2013) and mGluRs (Nicoletti et al. 2011). A very diverse range of receptor phosphorylation–
dephosphorylation events, auxiliary subunits, protein–protein interactions, and receptor trafficking 
have been identified as important regulators of GluR function and synaptic plasticity (Huganir and 
Nicoll 2013; Henley and Wilkinson 2016). Synaptic activity-induced changes in GluR responses have 
long been linked to learning and memory (Collingridge et al. 2013; Morris 2013).  Furthermore, 
dysfunction of GluRs have been implicated in a wide range of neurological and psychiatric disorders 
(Nicoletti et al. 2011; Paoletti et al. 2013; Golubeva et al. 2015).  
 
Key Features of the Glutamate Receptor Family 
The amino acid L-glutamate is the predominant neurotransmitter of the vast majority of excitatory 
synapses in the mammalian CNS. This ubiquitous neurotransmitter acts via the activation of a 
number of ionotropic (ligand-gated ion channels) and metabotropic (G-protein-coupled) GluRs. 
These receptors are involved in nearly all aspects of nervous system development and function 
including many forms of synaptic plasticity such as long-term potentiation (LTP) and long-term 
depression (LTD), mechanisms that are involved in learning and memory (Morris 2013; Huganir and 
Nicoll 2013). GluRs are also involved in a very wide range of neurological and psychiatric disorders 
including chronic neurodegenerative conditions (Lewerenz and Maher 2015; Miladinovic et al. 2015). 
They are thus also potential targets for therapies for CNS disorders (Nicoletti et al. 2011; Collingridge 
et al. 2013). 
 
Ionotropic Glutamate Receptors 
The related channel pore forming subunit proteins of glutamate-gated ion channels (iGluRs) are 
encoded by 18 genes in mammals. Based on their sequence homology, electrophysiological 
properties and pharmacological selectivity they are subdivided into four subtypes: AMPA, kainate, 
NMDA, and δ receptors (Fig. 1). All iGluRs share a common basic structure, which differs from other 
ligand-gate ion channels. iGluRs are formed from the tetrameric assembly of homologous subunits 
around a central ion pore (Traynelis et al. 2010). The membrane topology of the iGluR subunits 
consists of a large extracellular N-terminal domain and four hydrophobic membrane-associated 
domains (M1-4; Fig. 2a). M2 is a re-entrant loop in the phospholipid bilayer and represents the 
channel pore-forming region (Kumar and Mayer 2013). Each subunit carries its own ligand-binding 
site, which consists of residues that are distributed throughout both the distal N-terminal domain 
(called S1) and the extracellular loop between M3 and M4 (called S2; Fig. 2a; Kumar and Mayer 
2013). The S1S2 ligand-binding domain regions of some of the iGluR subunits have been isolated 
and crystalized with and without bound ligands (Kumar and Mayer 2013). X-ray analysis of these 
proteins and protein-ligand complexes elucidated fine molecular details of the binding site, and the 
conformational changes of different agonists and antagonists induce to open or block the ion 
channels or modulate the manifestation of their activity (Kumar and Mayer 2013). Crystallographic 
and cryogenic electron microscopy studies have provided detailed structures of the antagonist-
bound tetrameric GluA2 (Sobolevsky et al. 2009) and heteromeric GluA2/3 (Herguedas et al. 2016) 
AMPARs, which revealed complex subunit domain interactions within iGluRs (Fig. 2b). 
Oligomerization of iGluR subunits plays a major role in their surface expression (Herguedas et al. 
2013). Nonfunctional receptors are retained intracellularly, suggesting that glutamate binding and 
associated conformational changes are prerequisites for the forward trafficking of intracellular iGluRs 
following multimeric assembly (Herguedas et al. 2013). In addition to the pore-forming subunits, 
native iGluR protein complexes also contain auxiliary subunits and a wide variety of intracellular 
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interaction partners (Traynelis et al. 2010; Galaz et al. 2015). Auxiliary subunits are defined by four 
key criteria: (1) they are not an integral component of the transduction pathway, (2) they are stably 
associated with pore-forming subunits, (3) they affect multiple aspects of receptor pharmacology, 
function and subcellular trafficking or targeting, (4) their co-assembly is required for proper neuronal 
functionality of the receptor (Galaz et al. 2015; Howe 2015). In contrast, other interacting proteins 
are involved in transient and often dynamic interactions with iGluRs and they influence singular 
aspects of receptor function (e.g. biogenesis, trafficking or synaptic localization; Traynelis et 
al. 2010). These interactions allow local signaling to proceed, providing the possibility of spatial and 
temporal specificity to receptor regulation. Functional and immunolocalization studies indicate that 
segregated populations of iGluRs are localized at diverse subcellular compartments (Henley and 
Wilkinson 2016).  
 
AMPA receptors (AMPARs) mediate fast synaptic transmission in the CNS and they are key 
components of the modifiable synaptic response. AMPARs are formed by co-assembly of the GluA1-
4 channel pore-forming subunits (Fig. 1), each of which can form functional homomeric receptors, 
although most native AMPARs contain both the GluA2 subunit and either GluA1, GluA3, or GluA4 
(Traynelis et al. 2010). All AMPAR subunits exist as two splice variants termed flip and flop. The 
alternatively spliced region is in the extracellular loop (S2) adjacent to the last transmembrane 
domain (M4; Fig. 2a). The flip splice variants of GluA1-4 desensitize more slowly and to a lesser 
extent than the flop variants, which can influence the amplitude of the total AMPAR current (Traynelis 
et al. 2010). The C-terminal domain of AMPAR subunits also undergo alternative splicing to yield 
short and long forms of the intracellular domain (Traynelis et al. 2010). GluA2 undergoes editing in 
the M2 channel pore-forming region at the functionally significant Q/R site (Fig. 2a). The GluA2 
subunit in the edited form is responsible for the Ca2+ impermeability of AMPARs (Henley and 
Wilkinson 2016).  
Auxiliary subunits play a critical role in the regulation of AMPAR function and trafficking. The 
currently identified auxiliary subunits of AMPARs are: transmembrane AMPAR regulatory proteins 
(TARPs), suppressor of lurcher (SOL), cornichon homologues (CNIHs), synapse differentiation-
induced gene I (SynDIG I), cysteine-knot AMPAR modulating proteins 44 (CKAMP44 or Shisa9), 
and germ cell-specific gene 1-like (GSG1L) protein (Haering et al. 2014). 
AMPARs are highly mobile proteins that undergo constitutive and activity-dependent translocation 
to, and removal from, synapses (Henley and Wilkinson 2016). Increases in synaptic AMPAR function 
through changes in their number, subunit composition, and/or properties result in the long-term 
potentiation (LTP) of synaptic efficacy. Conversely, removal of synaptic AMPARs provides a 
mechanism for long-term depression (LTD) (Huganir and Nicoll 2013). Several functionally important 
phosphorylation sites have been identified in the C-terminal domains of AMPAR subunits (Traynelis 
et al. 2010; Diering et al. 2016). The effects of these phosphorylation/dephosphorylation events 
together with protein–protein interactions (e.g., α-actinin, AP2, GRIP, GRIP2, IQGAP1, mLIN-10, 
NSF, PICK1, PSD95, RIL, SAP97, Shank3, syntenin, 4.1; Traynelis et al. 2010) are crucial in 
functional changes, localization and trafficking of these receptors so that they can fulfill their roles in 
synaptic transmission and plasticity (Huganir and Nicholl 2013; Henley and Wilkinson 2016). 
 
Kainate receptors (KARs) are key players in the modulation of neuronal-network activity 
throughout the CNS (Lerma and Marques 2013). While other iGluRs (AMPA and NMDA receptors) 
mainly operate at postsynaptic sites, KARs are located at both presynaptic and postsynaptic sites 
where they modulate neurotransmitter release or mediate excitatory neurotransmission, respectively 
(Lerma and Marques 2013). KARs are also involved in neuronal differentiation, synaptic plasticity, 
epileptogenesis, chronic pain, neurodegeneration, neuronal cell death, migraine, schizophrenia, 
autism, bipolar disorders, mental retardation and periventricular leukomalacia (Lerma and Marques 
2013). Some of the functions of KARs involve metabotropic action through coupling with a G-protein, 
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which does not require an ionotropic action. For instance, KARs regulate neuronal excitability by 
inhibition of Ca2+-dependent K+ channels (Lerma and Marques 2013). 
Molecular cloning has identified five channel pore-forming KAR subunits, named GluK1-5 (Fig. 1; 
Traynelis et al. 2010; Lerma and Marques 2013). KAR subunits are subdivided into low-affinity 
(GluK1-3) and high-affinity (GluK4/5) kainate-binding subunits (Lerma and Marques 2013). 
Electrophysiological and biochemical analysis of recombinant KARs indicate that functional KAR 
channels are formed by both homomeric and heteromeric expression of GluK1-3 subunits. In 
contrast, the GluK4 and GluK5 subunits do not form functional homomeric channels, but they co-
assemble with the GluK1-3 subunits (Lerma and Marques 2013). The diversity of KARs is increased 
by the existence of splice variants for GluK1 (1a-d, 2a-c), GluK2 (a-c), and GluK3 (a,b) subunits 
(Fig. 1; Traynelis et al. 2010). GluK1 and GluK2 are subject to mRNA editing at the functionally 
significant Q/R site in the channel pore forming domain (Fig. 2a). Q/R editing of GluK1 and GluK2 
subunits reduces Ca2+-permeability of KARs (Traynelis et al. 2010). 
Studies with recombinant receptors in cell lines and cultured neurons have started to define rules 
for the trafficking of KARs to the plasma membrane. The relative level of their surface expression 
depends on subunit composition, alternative splicing of their C-terminal domains, and editing of the 
Q/R site in the pore forming M2 domain. Some subunits (GluK2a and GluK3a) contain a forward 
trafficking motif, whereas others (GluK1a, GluK1b, GluK2b, GluK3b, and GluK5) are retained in the 
endoplasmic reticulum due to retention signals (Traynelis et al. 2010). 
Neuropilin and tolloid-like 1 and 2 (Neto1 and Neto2) were identified as KAR auxiliary subunits 
that are responsible for the characteristic slow kinetics and high agonist affinity of native KARs 
(Copits and Swanson 2012). KAR subunits and splice variants show great divergence in their C-
terminal cytoplasmic domain, which has been identified as a region of interaction with a number of 
protein partners (Traynelis et al. 2010). Many KAR-interacting proteins have been identified (e.g., 
actifilin, calmodulin, CASK, COPI, cortactin, dynamin-1, dynamitin, G-α(q/11), GRIP/GRIP2, NSF, 
PICK1, profiling, PSD95, SAP97, SAP102, SNAP25, spectrin, SUMO, syntenin, VILIP1/3, 14-3-3). 
Some of these proteins have been implicated in trafficking, synaptic localization and modulation of 
the properties of KARs (Traynelis et al. 2010). 
 
NMDA receptors (NMDARs) function as modulators of synaptic response and coincidence 
detectors (Collingridge et al. 2013). At resting membrane potentials, NMDARs are inactive. This is 
due to a voltage-dependent block of the channel pore by Mg2+, preventing ion flows through it. 
Sustained activation of AMPARs by, for instance, a train of impulses arriving at a presynaptic 
terminal, depolarizes the postsynaptic cell, releasing the channel inhibition and thus allowing 
NMDAR activation. In addition to Na+ and K+, NMDARs are also permeable to Ca2+. Thus, NMDAR 
activation leads to a Ca2+ influx into the postsynaptic cells, a signal that is instrumental in the 
activation of a number of signaling cascades. Depending on the pattern of synaptic plasticity, 
NMDARs are responsible for a wide range of postsynaptic functions, including LTP and LTD 
(Collingridge et al. 2013). While the physiological significance remains to be determined, recent 
studies suggested a non-ionotropic signaling role for NMDARs, which is based on agonist-induced 
conformational changes in the receptor, independently of channel opening (Gray et al. 2016). 
Excessive activation of NMDARs leads to pathological processes (e.g., excitotoxic injury) in a 
number of acute and chronic neurological disorders (Miladinovic et al. 2015). 
NMDARs are obligate heterotetramers formed from assemblies of GluN1 with GluN2A-D and 
GluN3A/B channel pore-forming subunits (Fig. 1). In addition, GluN3A can assemble with GluN1 
(without other GluN2 subunits) to form excitatory, Ca2+-impermeant glycine receptors. Eight possible 
variations of the GluN1 subunit arise by alternative splicing of a single gene transcript. The insertion 
of one splice cassette at the N-terminal region of GluN1 and the deletion of two independent 
consecutive splice variants at the C terminus have been identified (Sanz-Clemente et al. 2013). 
Therefore, a large number of different NMDARs with differing functional and pharmacological 
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properties exist in different parts of the brain or at different stages in development (Molnár 2008). 
Unusually for the iGluR, L-glutamate is not the only agonist for the NMDAR. Glycine, another amino 
acid, is a co-agonist and both transmitters must bind in order for the receptor to function. The binding 
sites for glutamate and glycine are found on different subunits – glycine binds to the GluN1 subunit 
while glutamate binds to the GluN2 subunit. This is one reason why both subunit types are required 
to generate a fully functioning receptor. The GluN2B subunit also possesses a binding site for 
polyamines, regulatory molecules that modulate the functioning of NMDARs (Collingridge et al. 
2013).  
While previous studies raised the possibility that Neto1 and/or amyloid precursor protein (APP) 
are auxiliary subunits of NMDARs, further studies are necessary to confirm or discard these findings 
(Galaz et al. 2015). Like other iGluRs, NMDARs also interact with a wide range of cytoskeletal, 
scaffolding and signaling proteins (e.g., α-actin-2, AP2, calmodulin, CaMKII, CARPI, COPII, GPS2, 
LIN7, LIN10, MAP1S, PACSIN1, plectin, PSD95, RACK1, SALM1, SAP97, SAP102, S-SCAM; 
Traynelis et al. 2010; Collingridge et al. 2013). 
 
δ receptors (GluD1 and GluD2) share 17-28% amino acid sequence identity with other iGluR 
subfamilies. Despite structural similarities and the presence of amino acid residues critical to ligand 
binding and Ca2+ permeability, GluD subunits do not function as conventional glutamate-gated ion 
channels. However, recent studies suggest that postsynaptic GluD subunits form a molecular bridge 
with presynaptic β-neurexin 1 via Cbln1 (a C1q-like synaptic organizer) and they are involved in 
higher brain functions through controlling synaptic connectivity and plasticity (Elegheert et al. 2016). 
 
Metabotropic Glutamate Receptors 
mGluRs are members of class C G-protein coupled receptor family and they play important roles in 
regulating the activity of many synapses in the CNS (Niswender and Conn 2010). These receptors 
activate a multitude of signaling pathways; therefore, they are involved in a wide number of 
physiological and pathological processes: modulation of slow excitatory and inhibitory responses; 
the regulation of Ca2+, K+, and nonselective cation channels; the inhibition and facilitation of 
transmitter release; the induction of LTP/LTD; the formation of various types of memory; the 
regulation of iGluR trafficking; modification of AMPAR-, NMDAR- and KAR-mediated synaptic 
transmission; the regulation of neuronal development; and signaling between neurons and glial cells 
(Gladding et al. 2009; Niswender and Conn 2010). mGluRs are also implicated in various diseases 
such as epilepsy, anxiety and stress disorders, depression, schizophrenia, fragile X mental 
retardation, autism, Parkinson’s disease, chronic pain, drug addiction, hypoxic brain damage, and 
excitotoxic neuronal death (Nicoletti et al. 2011; Golubeva et al. 2015). 
The seven transmembrane-domain proteins mGluRs (Fig. 3) are coupled to heterotrimeric GTP-
binding proteins which link the receptors to downstream signaling pathways (Niswender and 
Conn 2010; Nicoletti et al. 2011). The family of mGluRs comprises eight different subtypes (mGlu1-
8 receptors; Fig. 1) classified into three groups on the basis of sequence similarities, pharmacological 
properties, and intracellular signal transduction mechanisms (Niswender and Conn 2010). Group I 
includes mGlu1 and mGlu5 receptors, which couple to Gq and activate signaling cascades involving 
phospholipase C (PLC), inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). In group II 
(mGlu2, mGlu3) and group III (mGlu4, mGlu6, mGlu7, and mGlu8) receptors couple to Gi/Go and 
inhibit adenylyl cyclise (AC) (Niswender and Conn 2010). Many of these receptors (mGlu1, mGlu3, 
mGlu5-8) exist as various isoforms with different intracellular C-termini generated by alternative 
splicing (Fig. 1; Niswender and Conn 2010). The large N-terminal domain of the mGluRs contains 
the ligand-binding site, which is formed by two-hinged globular domains – the so-called Venus fly 
trap domain (Fig. 3a, b; Nicoletti et al. 2011; Rondard and Pin 2015). Binding of glutamate causes 
the two domains to close, providing the structural change in the transmembrane domains that 
 5 
triggers intracellular G-protein activation. mGluRs form dimers stabilized by an inter-subunit disulfide 
bond (Fig. 3b). Only mGluR subtypes coupled to the same G-protein can form heterodimers (Nicoletti 
et al. 2011). The binding of a single agonist per dimer is sufficient for receptor activation (Nicoletti et 
al. 2011). mGluRs are expressed by neurons and glia, where they locate in the proximity of the 
synaptic cleft. In neurons, mGlu1/5 are mostly localized postsynaptically, mGlu4/7/8 at the 
presynapse, while mGlu2/3 do not show any preference. mGlu6 is only expressed in retinal bipolar 
cells postsynaptic to photoreceptors (Niswender and Conn 2010). Proteins interacting with mGluRs 
include: 4.1 G, adenosine receptor A1, Ca v2.1, Ca2+-sensing receptor, calmodulin, caveolin-1/-2β, 
GABAB1 receptor, filamin-A, G-protein βγ, GRIP, GRK2, homer, optineurin, pias1, PICK1, PKA, PKC, 
PP1γ1, PP2α, siah-1A, syntenin, tamalin, α/β-tubulin (Niswender and Conn 2010). 
 
Anti-GluR autoantibodies are present in a range of CNS disorders. A wide range of anti-GluR 
antibodies have been found in several different neurological and autoimmune diseases and they are 
much more prevalent than previously thought. Several studies have identified autoantibodies to 
GluA3, GluN1, GluN2A/B, mGlu1 and mGlu5 GluR proteins (reviewed in Levite 2014). The presence 
of these anti-GluR antibodies has been linked to neurological and psychiatric disorders, including 
epilepsy, encephalitis and stroke (Levite 2014). There is evidence that these autoimmune anti-GluR 
antibodies can bind to neurons in specific brain regions, activate GluRs, kill neurons by excitotoxicity 
and/or by complement-dependent mechanism (Levite 2014). 
 
Summary 
Glutamate is the most important excitatory neurotransmitter in the CNS, producing a wide range of 
synaptic responses through the activation of a mixed population of GluRs. While iGluRs are 
responsible for fast synaptic transmission, mGluRs modulate slow synaptic transmission through 
intracellular second messengers. Both iGluRs and mGluRs are critically important signaling 
molecules for normal brain function. They transduce the vast majority of excitatory 
neurotransmission and regulate the strength of both excitatory and inhibitory transmission in the 
CNS via complex interactions. Glutamatergic systems are dysfunctional in most neuropathologies, 
and aberrant receptor function appears to have causative roles in many neurological disorders. In 
addition to neurons, iGluRs and mGluRs have been identified in nonneuronal cells where they are 
involved in a broad range of signaling processes (Du et al. 2016). The full functional significance of 
these nonneuronal GluRs remains to be established. A confound in the study of GluRs has been the 
lack of congruence between the properties of recombinant receptors expressed in heterologous 
systems and those of native receptors studied in the brain tissue. This mismatch suggests that 
heterologously expressed receptors lack modulatory components that can influence essential 
properties. The discovery of auxiliary subunits for iGluRs (e.g., TARPS, Neto1/2; Galaz et al. 2015), 
dimerization of mGluRs (Rondard and Pin 2015), various interaction partners, 
phosphorylation/dephosphorylation and other covalent modifications of GluRs (Niswender and 
Conn 2010; Traynelis et al. 2010) has started to provide answers for many of these discrepancies. 
A better understanding of the specific functions and molecular interactions of native GluR subtypes 
and the development of more subtype/subunit-specific pharmacological tools are needed for future 
breakthroughs in the treatment of several neurological and psychiatric disorders. 
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Figure legends 
 
Glutamate Receptors, Fig. 1. IUPHAR recommended nomenclature, classification and sequence 
homology dendrograms of iGluR and mGluR proteins. The known splice variants and main signaling 
mechanisms are indicated next to the code name of the GluR proteins. 
 
Glutamate Receptors, Fig. 2. (a) Schematic representation of iGluR subunit membrane topology. 
iGluR subunits composed of two extracellular domains: the N-terminal domain (NTD) and the ligand-
binding domain (LBD) formed by the S1 and S2 segments. Unlike other ligand-gated ion channels 
(e.g., nicotinic acetylcholine receptors, GABA A receptors), iGluRs contain three transmembrane 
domains (M1, M3, and M4). A membrane re-entrant loop (M2) forms the pore of the channel in 
iGluRs and contains the Q/R editing site in GluA2, GluK1, and GluK2 subunits. The intracellular C-
terminal domain (CTD) contains phosphorylation sites and binds to intracellular proteins. See text 
for details. Schematic image was provided by Dr. Andrew Doherty. (b) Assembled iGluR subunits 
have an overall twofold symmetry perpendicular to the membrane plane; the extracellular N-terminal 
domains (NTDs) and ligand-binding domains (LBDs) are organized as dimmers of dimmers, and the 
ion channel forming membrane-associated domains (M1-4) exhibit a fourfold symmetry (Sobolevsky 
et al. 2009). 
 
Glutamate Receptors, Fig. 3. Schematic representation of mGluR membrane topology (a) and 
diagram of the mGluR dimer (b). mGluRs contain large extracellular domains called the Venus flytrap 
domains (VFDs), which bind L-glutamate and other ligands. The cysteine-rich domain (CRD) links 
the VFD to the seven transmembrane domains (M1-7). The intracellular C-terminal domain (CTD) is 
often subject to alternative splicing to generate different C-terminal tails. The open state of the VFD 
is the inactive state and can be stabilized by antagonists. Schematic images were provided by Dr. 
Andrew Doherty. 
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